Crossmark

Enhancing COVID Rehabilitation with Technology (ECORT): protocol for an open-label, single-site randomized controlled trial evaluating the effectiveness of electronic case management for individuals with persistent COVID-19 symptoms

Crossref DOI link: https://doi.org/10.1186/s13063-022-06578-1

Published Online: 2022-09-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hatcher, Simon http://orcid.org/0000-0003-3117-2350
Werier, Joel

Edgar, Nicole E.

Booth, James

Cameron, D. William J.

Corrales-Medina, Vicente

Corsi, Daniel

Cowan, Juthaporn

Giguère, Pierre

Kaluzienski, Mark

Marshall, Shawn

Mestre, Tiago

Mulligan, Bryce

Orpana, Heather

Pontefract, Amanda

Stafford, Darlene

Thavorn, Kednapa

Trudel, Guy
Funding

Funding for this research was provided by:

Canadian Institutes of Health Research (466900)
License Information

Text and Data Mining valid from 2022-09-02

Version of Record valid from 2022-09-02
More Information

Article History

Received: 3 June 2022

Accepted: 20 July 2022

First Online: 2 September 2022

Declarations

:

: Ethics approval for this study has been granted by the Ottawa Health Sciences Network Research Ethics Board (OHSN-REB) (Protocol ID: 20210533-01H). Written, informed consent to participate will be obtained from all participants.

: Model consent form available from corresponding author on request.

: MK has consulting or speaking fees, unrelated to this trial or intervention, from HLS, Janssen, Otsuka, and Lundbeck in the last 2 years. TM, unrelated to this trial or intervention, has been a consultant for CHDI, Sunovion, Valeo Pharma, Roche, Biogen, and nQ Medical and has been involved in Speakers Bureaus for Abbvie and Valeo Pharma.The other authors declare that they have no competing interests.

Document is current

Any future updates will be listed below